BackgroundMetabolic-associated fatty liver disease (MAFLD) is characterized by excessive hepatic lipid accumulation, with limited safe and effective therapeutic options currently available. Previous studies have demonstrated that mangiferin (MAN) alleviates nonalcoholic fatty liver disease via modulation of the AMPK and NLRP3 signaling pathways. However, there are no reports to date investigating whether MAN exerts anti-MAFLD effects by regulating bile acid (BAs) metabolism and its underlying mo